臨床泌尿器科63巻5号

2009年04月発行

特集 泌尿器科の癌薬物療法―ここが聞きたい

精巣腫瘍―“poor risk”の標準的導入化学療法はBEPか？―予後不良群に対する治療戦略

著者： 堀川洋平¹ 土谷順彦¹ 羽渕友則¹

所属機関： ¹秋田大学医学部生殖発達医学講座泌尿器科学分野

ページ範囲：P.345 - P.350

文献概要

要旨　精巣腫瘍は，化学療法の進歩によりその90％以上が長期生存可能で，根治可能な固形腫瘍の好例である。しかし，転移期胚細胞腫のInternational Germ Cell Consensus Classification（IGCC分類）におけるpoor risk群では，治療後の5年非再発生存率は41％と満足のいくものではない。Poor risk群に対してはBEP療法4コースが標準的導入療法として推奨されているが，治療成績向上を目指してさまざまなレジメンが考案されてきた。しかしながら，現在までの臨床試験からはBEP療法を凌駕するレジメンは見出されず，今後の新たなレジメンの開発，臨床試験の結果が待たれる。

参考文献

1）Feldman DR, Bosl GJ, Sheinfeld J, et al：Medical treatment of advanced testicular cancer. JAMA 299：672-684, 2008

2）International Germ Cell Cancer Collaborative Group：International Germ Cell Consensus Classification：a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15：594-603, 1997

3）Williams SD, Birch R, Einhorn LH, et al：Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastin or etoposide. N Eng J Med 316：1435-1440, 1987

4）Einhorn LH：Curing metastatic testicular cancer. Proc Natl Acad Sci U S A 99：4592-4595, 2002

5）van Dijk MR, Steyerberg EW and Habbema JD：Survival of non-seminomatous germ cell cancer patients according to the IGCC classification：an update based on meta-analysis. Eur J Cancer 42：820-826, 2006

6）Shintaku I, Satoh M, Okajima E, et al：Survival of metastatic germ cell cancer patients assessed by international germ cell consensus classification in Japan. Jpn J Clin Oncol 38：281-287, 2008

7）Nichols CR, Williams SD, Loehrer PJ, et al：Randomized study of cisplatin dose intensity in poor-risk germ cell tumors：a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9：1163-1172, 1991

8）de Wit R, Stoter G, Sleijfer DT, et al：Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma：a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 71：1311-1314, 1995

9）Kaye SB, Mead GM, Fossa S, et al：Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor：a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 16：692-701, 1998

10）Nichols CR, Catalano PJ, Crawford ED, et al：Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors：an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 16：1287-1293, 1998

11）Motzer RJ, Nichols CJ, Margolin KA, et al：Phase Ⅲ randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 25：247-256, 2007

12）Culine S, Kramar A, Theodore C, et al：Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate-and poor-risk metastatic nonseminomatous germ cell tumors：Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol 26：421-427, 2008

13）McCaffrey JA, Mazumdar M, Bajorin DF, et al：Ifosfamide and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors：response and survival. J Clin Oncol 15：2559-2563, 1997

14）Hinton S, Catalano PJ, Einhorn LH, et al：Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors：final analysis of an intergroup trial. Cancer 97：1869-1875, 2003

15）Logothetis CJ, Samuels ML, Selig DE, et al：Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors：results with 100 patients. Am J Med 81：219-228, 1986

16）Schmoll HJ, Kollmannsberger C, Metzner B, et al：Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer：an extended phase Ⅰ/Ⅱ study of the German Testicular Cancer Study Group. J Clin Oncol 21：4083-4091, 2003

17）Christian JA, Huddart RA, Norman A, et al：Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J Clin Oncol 21：871-877, 2003

18）Fossa SD, Paluchowska B, Horwich A, et al：Intensive induction chemotherapy with C-BOP/BEP for intermediate-and poor-risk metastatic germ cell tumours（EORTC trial 30948）. Br J Cancer 93：1209-1214, 2005

19）Motzer RJ, Chou TC, Schwartz L, et al：Paclitaxel in germ cell cancer. Semin Oncol 22：12-15, 1995

20）Motzer RJ, Bajorin DF, Schwartz LH, et al：Phase Ⅱ trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 12：2277-2283, 1994

21）de Wit R, Louwerens M, de Mulder PH, et al：Management of intermediate-prognosis germ-cell cancer：results of a phase Ⅰ/Ⅱ study of Taxol-BEP. Int J Cancer 83：831-833, 1999

22）Hartmann JT, Gauler T, Metzner B, et al：Phase Ⅰ/Ⅱ study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group. J Clin Oncol 25：5742-5747, 2007

23）Motzer RJ, Sheinfeld J, Mazumdar M, et al：Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 18：2413-2418, 2000

24）Kawai K, Miyazaki J, Tsukamoto S, et al：Paclitaxel, ifosfamide and cisplatin regimen is feasible for Japanese patients with advanced germ cell cancer. Jpn J Clin Oncol 33：127-131, 2003

25）Pectasides D, Pectasides E, Papaxoinis G, et al：Methotrexate, paclitaxel, ifosfamide, and cisplatin in poor-risk nonseminomatous germ cell tumors. Urol Oncol. 2008 Dec 24［Epub ahead of print］

26）Toner GC, Geller NL, Tan C, et al：Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res 50：5904-5910, 1990

27）Mazumdar M, Bajorin DF, Bacik J, et al：Predicting outcome to chemotherapy in patients with germ cell tumors：the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol 19：2534-2541, 2001

28）Fizazi K, Culine S, Kramar A, et al：Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 22：3868-3876, 2004

29）Ishioka J, Kageyama Y, Ichiyanagi N, et al：Incorporation of TIP（paclitaxel, ifosfamide, cisplatin）into first-line therapy for intermediate to poor risk testicular germ cell tumors with unfavorable marker decline after initial two cycles chemotherapy：a report of three cases. Int J Urol 14：455-457, 2007